Ibrutinib heart risks under the microscope: can we predict them?
NCT ID NCT05939752
First seen Feb 28, 2026 · Last updated May 24, 2026 · Updated 12 times
Summary
This study aimed to understand why some people taking the cancer drug ibrutinib develop heart problems like atrial fibrillation (irregular heartbeat) and high blood pressure. Researchers planned to follow 8 patients with blood cancers, using heart tests and blood markers to find early warning signs. The study was ended early, so results are limited, but it highlights the need to monitor heart health during ibrutinib treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IBRUTINIB TREATMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chu Dijon Bourgogne
Dijon, 21000, France
Conditions
Explore the condition pages connected to this study.